Mycolactone Is Responsible for the Painlessness of Mycobacterium ulcerans Infection (Buruli Ulcer) in a Murine Study
Authors:
Open Access
- 1 May 2008
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 76 (5) , 2002-2007
Abstract
Buruli ulcer is a chronic skin disease caused by Mycobacterium ulcerans , which produces a toxic lipid mycolactone. Despite the extensive necrosis and tissue damage, the lesions are painless. This absence of pain prevents patients from seeking early treatment and, as a result, many patients experience severe sequelae, including limb amputation. We have reported that mice inoculated with M. ulcerans show loss of pain sensation and nerve degeneration. However, the molecules responsible for the nerve damage have not been identified. In order to clarify whether mycolactone alone can induce nerve damage, mycolactone A/B was injected to footpads of BALB/c mice. A total of 100 μg of mycolactone induced footpad swelling, redness, and erosion. The von Frey sensory test showed hyperesthesia on day 7, recovery on day 21, and hypoesthesia on day 28. Histologically, the footpads showed epidermal erosion, moderate stromal edema, and moderate neutrophilic infiltration up to day 14, which gradually resolved. Nerve bundles showed intraneural hemorrhage, neutrophilic infiltration, and loss of Schwann cell nuclei on days 7 and 14. Ultrastructurally, vacuolar change of myelin started on day 14 and gradually subsided by day 42, but the density of myelinated fibers remained low. This study demonstrated that initial hyperesthesia is followed by sensory recovery and final hypoesthesia. Our present study suggests that mycolactone directly damages nerves and is responsible for the absence of pain characteristic of Buruli ulcer. Furthermore, mice injected with 200 μg of mycolactone showed pulmonary hemorrhage. This is the first study to demonstrate the systemic effects of mycolactone.Keywords
This publication has 12 references indexed in Scilit:
- Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcerMicrobes and Infection, 2006
- Buruli ulcer: emerging from obscurityThe Lancet, 2006
- Mycobacterium ulcerans infection: control, diagnosis, and treatmentThe Lancet Infectious Diseases, 2006
- Infection withMycobacterium ulceransInduces Persistent Inflammatory Responses in MiceInfection and Immunity, 2005
- Findings from a buruli ulcer mouse model study.2005
- HIGH RATES OF APOPTOSIS IN HUMAN MYCOBACTERIUM ULCERANS CULTURE-POSITIVE BURULI ULCER SKIN LESIONSThe American Journal of Tropical Medicine and Hygiene, 2005
- Buruli Ulcer: A Systemic DiseaseClinical Infectious Diseases, 2003
- Mycobacterium ulceransCytotoxicity in an Adipose Cell ModelInfection and Immunity, 2001
- AMycobacterium ulceransToxin, Mycolactone, Causes Apoptosis in Guinea Pig Ulcers and Tissue Culture CellsInfection and Immunity, 2000
- Mycolactone: A Polyketide Toxin from Mycobacterium ulcerans Required for VirulenceScience, 1999